AstraZeneca and Palatin have amended their January 2007 global licensing and research agreement to discover, develop and commercialize compounds targeting melanocortin receptors.     Under the amendment, Palatin has agreed to license additional compounds and associated intellectual property to AZ. Palatin will receive development and regulatory milestone payments if any additional compound advances into human clinical trials, as well as sales milestone payments and royalties if any additiona...